Abstract:Machine learning methods offer time- and cost-effective means for identifying novel chemical matter as well as guiding experimental efforts to map enormous compound-kinase interaction spaces. However, considerable challenges for compound-kinase interaction modeling arise from the heterogeneity of available bioactivity readouts, including single-dose compound profiling results, such as percentage inhibition, and multi-dose-response results, such as IC . Standard activity prediction approaches utilize only dose-response data in the model training, disregarding a substantial portion of available information contained in single-dose measurements. Here, we propose a novel machine learning methodology for compound-kinase activity prediction that leverages both single-dose and dose-response data. Our two-stage model first learns a mapping between single-dose and dose-response bioactivity readouts, and then generates proxy dose-response activity labels for compounds that have only been tested in single-dose assays. The predictions from the first-stage model are then integrated with experimentally measured dose-response activities to model compound-kinase binding based on chemical structures and kinase features. We demonstrate that our two-stage approach yields accurate activity predictions and significantly improves model performance compared to training solely on dose-response labels, particularly in the most practical and challenging scenarios of predicting activities for new compounds and new compound scaffolds. This superior performance is consistent across five evaluated machine learning methods, including traditional models such as random forest and kernel learning, as well as deep learning-based approaches. Using the best performing model, we carried out extensive experimental profiling on a total of 347 selected compound-kinase pairs, achieving a high hit rate of 40% and a negative predictive value of 78%. We show that these rates can be improved further by incorporating model uncertainty estimates into the compound selection process. By integrating multiple activity data types, we demonstrate that our approach holds promise for facilitating the development of training activity datasets in a more efficient and cost-effective way.

Guided docking as a data generation approach facilitates structure-based machine learning on kinases

Docking-informed machine learning for kinome wide affinity prediction

A Simple Way to Incorporate Target Structural Information in Molecular Generative Models

Calibrated geometric deep learning improves kinase–drug binding predictions

Structure-Based de Novo Molecular Generator Combined with Artificial Intelligence and Docking Simulations

A Hybrid Structure-Based Machine Learning Approach for Predicting Kinase Inhibition by Small Molecules

Combining Docking Pose Rank and Structure with Deep Learning Improves Protein–Ligand Binding Mode Prediction over a Baseline Docking Approach

Using the Structural Kinome to Systematize Kinase Drug Discovery

Pose Ensemble Graph Neural Networks to Improve Docking Performances.

De Novo Structure-Based Drug Design Using Deep Learning

Improving drug discovery with a hybrid deep generative model using reinforcement learning trained on a Bayesian docking approximation

Learning to design drug-like molecules in three-dimensional space using deep generative models

Lessons learned during the journey of data: from experiment to model for predicting kinase affinity, selectivity, polypharmacology, and resistance

Addressing docking pose selection with structure-based deep learning: Recent advances, challenges and opportunities

Modern machine‐learning for binding affinity estimation of protein–ligand complexes: Progress, opportunities, and challenges

Approach for the Design of Covalent Protein Kinase Inhibitors via Focused Deep Generative Modeling

Efficient Exploration of Chemical Space with Docking and Deep Learning

Active site sequence representation of human kinases outperforms full sequence for affinity prediction and inhibitor generation: 3D effects in a 1D model

Leveraging Machine Learning and AlphaFold2 Steering to Discover State-Specific Inhibitors Across the Kinome

Leveraging multiple data types for improved compound-kinase bioactivity prediction

Structure-based <i>de novo</i> drug design using 3D deep generative models